Polly Niravath
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Polly Niravath has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Mothaffar F. Rimawi
Baylor College of Medicine, Houston, TX, USA
3 shared publications - C. Kent Osborne
Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, USA
2 shared publications Susan G. Hilsenbeck
Smith Breast Center At BCM, Houston, TX
2 shared publicationsTao Wang
Baylor College of Medicine, Houston, TX
2 shared publications- Alejandro Contreras
Department of Molecular and Cellular Biology and Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, 77030, TX, USA
1 shared publication Angel Rodriguez
The Methodist Hospital, Houston, Texas, USA
1 shared publication
Latest Publications
- 20 May 2017
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35 (15_suppl) , 10088
Scalp Cooling Alopecia Prevention trial (SCALP) for patients with early stage breast cancer.
10088 Background: Adjuvant chemotherapy decreases the risk of recurrence. However, it has distressing side effects, including alopecia. There are no randomized trials assessing modern scalp cooling to prevent alopecia, and success rates in non-randomized trials have varied. Methods: We conducted a multi-center randomized trial to evaluate the safety and efficacy of the Orbis Paxman Hair Loss Prevention System (OPHLPS) in reducing chemotherapy-induced alopecia. Women with stage I-II breast cancer planned to receive anthracycline- or taxane- based chemotherapy for at least four cycles were eligible and randomized in a 2:1 ratio to scalp-cooling or control. Scalp-cooling was done with the OPHLPS 30 minutes prior to, during and 90 minutes after each chemotherapy. The primary efficacy endpoints were hair preservation and device safety. We planned to enroll 235 subjects to provide 85% power to detect a 20% difference in hair preservation. Secondary endpoints included wig/scarf use and quality of life assessed by the EORTC QLQ-30, HADS and BIS. Subjects will be followed for 5 years for recurrence, overall survival, and site of recurrence. One interim analysis was planned to allow the study to stop early for efficacy after 142 subjects were enrolled and evaluable for the primary endpoint. To maintain the overall type 1 error rate, an O’Brien-Fleming spending function was used (interim boundary p = 0.0061). Results: This is the first randomized trial with modern scalp cooling in the world. For the interim analysis, 142 subjects were evaluable. Among them, 48 (50.5%) out of 95 in the cooling group and 0 (0%) out of 47 in the control group had hair preservation. The one-tailed p-value from the Fisher’s exact test is < 0.0001, which crosses the superiority boundary (p = 0.0061). Thus on 9/26/2016 the DSMB stopped the study early. The interim analysis was presented at SABCS 2016. There are 195 subjects enrolled on this clinical trial, and the final subject will be evaluable for the primary outcome February 2017. The final analysis will be presented. Conclusions: Our trial showed that scalp cooling using OPHLPS is highly effective in hair retention. Paxman Coolers has applied for FDA clearance for the OPHLPS based on the results of the interim analysis. Clinical trial information: NCT01986140.
- 20 May 2017
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35 (15_suppl) , 10088
Scalp Cooling Alopecia Prevention trial (SCALP) for patients with early stage breast cancer.
10088 Background: Adjuvant chemotherapy decreases the risk of recurrence. However, it has distressing side effects, including alopecia. There are no randomized trials assessing modern scalp cooling to prevent alopecia, and success rates in non-randomized trials have varied. Methods: We conducted a multi-center randomized trial to evaluate the safety and efficacy of the Orbis Paxman Hair Loss Prevention System (OPHLPS) in reducing chemotherapy-induced alopecia. Women with stage I-II breast cancer planned to receive anthracycline- or taxane- based chemotherapy for at least four cycles were eligible and randomized in a 2:1 ratio to scalp-cooling or control. Scalp-cooling was done with the OPHLPS 30 minutes prior to, during and 90 minutes after each chemotherapy. The primary efficacy endpoints were hair preservation and device safety. We planned to enroll 235 subjects to provide 85% power to detect a 20% difference in hair preservation. Secondary endpoints included wig/scarf use and quality of life assessed by the EORTC QLQ-30, HADS and BIS. Subjects will be followed for 5 years for recurrence, overall survival, and site of recurrence. One interim analysis was planned to allow the study to stop early for efficacy after 142 subjects were enrolled and evaluable for the primary endpoint. To maintain the overall type 1 error rate, an O’Brien-Fleming spending function was used (interim boundary p = 0.0061). Results: This is the first randomized trial with modern scalp cooling in the world. For the interim analysis, 142 subjects were evaluable. Among them, 48 (50.5%) out of 95 in the cooling group and 0 (0%) out of 47 in the control group had hair preservation. The one-tailed p-value from the Fisher’s exact test is < 0.0001, which crosses the superiority boundary (p = 0.0061). Thus on 9/26/2016 the DSMB stopped the study early. The interim analysis was presented at SABCS 2016. There are 195 subjects enrolled on this clinical trial, and the final subject will be evaluable for the primary outcome February 2017. The final analysis will be presented. Conclusions: Our trial showed that scalp cooling using OPHLPS is highly effective in hair retention. Paxman Coolers has applied for FDA clearance for the OPHLPS based on the results of the interim analysis. Clinical trial information: NCT01986140.
- 28 June 2016
- Published by Springer Nature in Current Breast Cancer Reports
- Vol. 8 (3) , 135-138
Aromatase Inhibitor-Associated Arthralgia: How Big Is the Problem and What Can Be Done?
- 28 June 2016
- Published by Springer Nature in Current Breast Cancer Reports
- Vol. 8 (3) , 135-138
Aromatase Inhibitor-Associated Arthralgia: How Big Is the Problem and What Can Be Done?
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 10020
Vitamin D and aromatase inhibitor-induced arthralgia: Analysis of Canadian cancer trial group MA.27 data.
10020 Background: Approximately half of the women who take aromatase inhibitor (AI) therapy will develop joint pain, termed aromatase inhibitor-induced arthralgia (AIA). AIA becomes so painful that up to 20% of women will discontinue AI’s because of it. However, there is no standard treatment for this common, though poorly understood, problem. Methods: Using plasma samples from the MA.27 study, we identified 72 cases (with AIA) and 144 matched controls. We compared change in vitamin D level between baseline and 6 months in 204 cases and controls. We also correlated inflammatory cytokines with development of AIA. We measured 9 inflammatory cytokines which are implicated in low estrogen states, arthritis, and/or vitamin D deprivation -- Il-1, IL-6, TNF-α, IFNg, IL-10, IL-12p70, IL-17, IL-23, and CCL-20. Finally, we aimed to develop a multivariate model to predict for AIA using baseline factors such as vitamin D level, previously identified musculoskeletal SNP’s, age, BMI, and vitamin D receptor polymorphism. Results: After correcting for seasonal and geographic variation, the month 6 Vitamin D plasma levels increased by 4.52 ng/mL (p = 0.049), suggesting intake of vitamin D. However, there was no difference in the change in vitamin D levels between cases and controls. Elevated inflammatory cytokines were not correlated with the development of AIA. However, those with the Vitamin D receptor (VDR) FOK-I polymorphism were more likely to have a lower IL-1β level after 6 months of use as compared to those with wildtype VDR. In the multivariate model, the clinical factors listed above did not reliably predict development of AIA in this subset of patients. Conclusions: In this retrospective study, there is no correlation between vitamin D levels and the development of AIA. However, vitamin D receptor polymorphisms may explain some of the variation in individual responses to Vitamin D replacement. Patients with the Fok-I VDR polymorphism were more likely to have a significant reduction in IL-1β level.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 10020
Vitamin D and aromatase inhibitor-induced arthralgia: Analysis of Canadian cancer trial group MA.27 data.
10020 Background: Approximately half of the women who take aromatase inhibitor (AI) therapy will develop joint pain, termed aromatase inhibitor-induced arthralgia (AIA). AIA becomes so painful that up to 20% of women will discontinue AI’s because of it. However, there is no standard treatment for this common, though poorly understood, problem. Methods: Using plasma samples from the MA.27 study, we identified 72 cases (with AIA) and 144 matched controls. We compared change in vitamin D level between baseline and 6 months in 204 cases and controls. We also correlated inflammatory cytokines with development of AIA. We measured 9 inflammatory cytokines which are implicated in low estrogen states, arthritis, and/or vitamin D deprivation -- Il-1, IL-6, TNF-α, IFNg, IL-10, IL-12p70, IL-17, IL-23, and CCL-20. Finally, we aimed to develop a multivariate model to predict for AIA using baseline factors such as vitamin D level, previously identified musculoskeletal SNP’s, age, BMI, and vitamin D receptor polymorphism. Results: After correcting for seasonal and geographic variation, the month 6 Vitamin D plasma levels increased by 4.52 ng/mL (p = 0.049), suggesting intake of vitamin D. However, there was no difference in the change in vitamin D levels between cases and controls. Elevated inflammatory cytokines were not correlated with the development of AIA. However, those with the Vitamin D receptor (VDR) FOK-I polymorphism were more likely to have a lower IL-1β level after 6 months of use as compared to those with wildtype VDR. In the multivariate model, the clinical factors listed above did not reliably predict development of AIA in this subset of patients. Conclusions: In this retrospective study, there is no correlation between vitamin D levels and the development of AIA. However, vitamin D receptor polymorphisms may explain some of the variation in individual responses to Vitamin D replacement. Patients with the Fok-I VDR polymorphism were more likely to have a significant reduction in IL-1β level.
- Open Access
- 6 January 2015
- Published by Springer Nature in Experimental Hematology & Oncology
- Vol. 4 (1) , 1
Breast adenocarcinoma recurring as small cell carcinoma in a patient with a germline BRCA2 mutation: clonal evolution unchecked
Because up to 30% of breast cancer cases may relapse, understanding the biology of recurrent breast cancer is imperative in preventing these poor outcomes. Thus, we present this unusual case of a BRCA2 carrier who presented seven years after her initial diagnosis of breast adenocarcinoma with a new lump in the left axillary tail, which proved to be small cell carcinoma. The second cancer bore no morphologic or immunohistochemical resemblance to the first. However, we aimed to understand whether the two cancers could have been related.
- 6 January 2015
- Published by Springer Nature in Experimental Hematology & Oncology
- Vol. 4 (1) , 1
Open AccessBreast adenocarcinoma recurring as small cell carcinoma in a patient with a germline BRCA2 mutation: clonal evolution unchecked
Because up to 30% of breast cancer cases may relapse, understanding the biology of recurrent breast cancer is imperative in preventing these poor outcomes. Thus, we present this unusual case of a BRCA2 carrier who presented seven years after her initial diagnosis of breast adenocarcinoma with a new lump in the left axillary tail, which proved to be small cell carcinoma. The second cancer bore no morphologic or immunohistochemical resemblance to the first. However, we aimed to understand whether the two cancers could have been related.
- 20 November 2014
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 32 (33) , 3779
Aromatase Inhibitor Adverse Effects: Are We Sweeping Them Under the Rug?
- 20 November 2014
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 32 (33) , 3779
Aromatase Inhibitor Adverse Effects: Are We Sweeping Them Under the Rug?
- Open Access
- 6 November 2014
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 20 (1) , 13
A Phase II Trial of Capecitabine Concomitantly With Whole-Brain Radiotherapy Followed by Capecitabine and Sunitinib for Brain Metastases From Breast Cancer
Brain metastasis from breast cancer presents a significant threat to women's health and quality of life. Capecitabine and sunitinib have shown some activity in this setting; therefore, we conducted a single-arm phase II trial with these agents. Patients with breast cancer and central nervous system (CNS) metastases received whole-brain radiotherapy concurrently with capecitabine (1,000 mg/m2 per day for 14 consecutive days), followed by concomitant capecitabine (2,000 mg/m2 per day for 2 weeks followed by a 1-week break) and sunitinib (37.5 mg daily, continuously). The primary endpoint was progression-free survival (PFS). Of 25 planned patients that would be required to detect a 4-month improvement (from 5 to 9 months) in median PFS with 80% power, 12 were enrolled, and the study was then closed for slow accrual. Median PFS was 4.7 months, and median overall survival was 10 months. In the CNS, 25% had progressive disease, and 83% experienced extra-CNS progression. The most common side effects were fatigue and nausea. In 12 evaluable patients studied, concurrent capecitabine and whole-brain radiation followed by capecitabine and sunitinib did not extend PFS over historical rates and was associated with significant toxicity. Our study was small and closed due to slow accrual.
- 6 November 2014
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 20 (1) , 13
Open AccessA Phase II Trial of Capecitabine Concomitantly With Whole-Brain Radiotherapy Followed by Capecitabine and Sunitinib for Brain Metastases From Breast Cancer
Brain metastasis from breast cancer presents a significant threat to women's health and quality of life. Capecitabine and sunitinib have shown some activity in this setting; therefore, we conducted a single-arm phase II trial with these agents. Patients with breast cancer and central nervous system (CNS) metastases received whole-brain radiotherapy concurrently with capecitabine (1,000 mg/m2 per day for 14 consecutive days), followed by concomitant capecitabine (2,000 mg/m2 per day for 2 weeks followed by a 1-week break) and sunitinib (37.5 mg daily, continuously). The primary endpoint was progression-free survival (PFS). Of 25 planned patients that would be required to detect a 4-month improvement (from 5 to 9 months) in median PFS with 80% power, 12 were enrolled, and the study was then closed for slow accrual. Median PFS was 4.7 months, and median overall survival was 10 months. In the CNS, 25% had progressive disease, and 83% experienced extra-CNS progression. The most common side effects were fatigue and nausea. In 12 evaluable patients studied, concurrent capecitabine and whole-brain radiation followed by capecitabine and sunitinib did not extend PFS over historical rates and was associated with significant toxicity. Our study was small and closed due to slow accrual.
- Open Access
- 6 March 2013
- Published by Elsevier in Annals of Oncology
- Vol. 24 (6) , 1443-1449
Aromatase inhibitor-induced arthralgia: a review
Though aromatase inhibitors (AIs) are an essential part of estrogen receptor-positive (ER+) breast cancer therapy, many patients discontinue the medicine before their adjuvant therapy is completed because of the arthralgia which often accompanies the medicine. Up to half of women on AI therapy experience joint pain, and up to 20% will become non-compliant with the medicine because of the joint pain. Yet, very little is known about what causes AI-induced arthralgia (AIA), and there is no established, effective treatment for this difficult problem. It compromises survivors’ quality of life and leads to non-compliance. This paper will discuss AIA in depth, including potential etiologies, clinical significance, risk factors, and possible management solutions. Of note, this article presents one of the first proposed algorithms which clearly lays out a treatment plan for AIA, incorporating a variety of interventions which have been proven by the available literature.
- 6 March 2013
- Published by Elsevier in Annals of Oncology
- Vol. 24 (6) , 1443-1449
Open AccessAromatase inhibitor-induced arthralgia: a review
Though aromatase inhibitors (AIs) are an essential part of estrogen receptor-positive (ER+) breast cancer therapy, many patients discontinue the medicine before their adjuvant therapy is completed because of the arthralgia which often accompanies the medicine. Up to half of women on AI therapy experience joint pain, and up to 20% will become non-compliant with the medicine because of the joint pain. Yet, very little is known about what causes AI-induced arthralgia (AIA), and there is no established, effective treatment for this difficult problem. It compromises survivors’ quality of life and leads to non-compliance. This paper will discuss AIA in depth, including potential etiologies, clinical significance, risk factors, and possible management solutions. Of note, this article presents one of the first proposed algorithms which clearly lays out a treatment plan for AIA, incorporating a variety of interventions which have been proven by the available literature.
- Open Access
- 17 March 2011
- Published by BMJ in Frontline Gastroenterology
- Vol. 2 (3) , 182-187
Utility of screening for hepatocellular carcinoma among cirrhotics
Background Screening known cirrhotics for hepatocellular cancer (HCC) has long been a contentious topic. Studies to date have failed to conclusively prove or disprove the validity of α-fetoprotein (AFP) and hepatic ultrasound as screening mechanisms for HCC among cirrhotics, particularly in the American population. It is not clear whether these screening mechanisms provide any benefit in terms of reduced morbidity and mortality. Methods The study examined all patients with liver cirrhosis who developed HCC at the Michael E DeBakey VA Medical Center between 1999 and 2005. Those who were screened with AFP and/or imaging (either ultrasound, triphasic liver protocol CT or MRI) were compared with those patients who were not screened at all. The screened and unscreened patients were compared in terms of Barcelona Clinic Liver Cancer (BCLC) stage at the time of diagnosis. Results Statistical analysis revealed a significant difference between the screened and unscreened groups in terms of BCLC stage at diagnosis, with the unscreened group being diagnosed at later stages than the screened group. Of the 155 patients observed, 26 were appropriately screened, and 129 were not. The BCLC stages at diagnosis for the two groups were as follows: screened patients: 34.6%, 38.5%, 7.7% and 19.2% for BCLC stages A, B, C and D, respectively; unscreened patients: 12.4%, 24.8%, 27.1% and 35.7% for BCLC stages A, B, C and D, respectively. The different trend in the two groups was found to be statistically significant, with a p value of 0.004. Furthermore, among the screened group, no particular method of screening (AFP vs imaging vs combination) was shown to be superior to another. Conclusions Screening for HCC among cirrhotics using AFP and/or imaging every 6 months does correlate with HCC diagnosis at an earlier BCLC stage, thus portending better treatment options and improved prognosis. Therefore, screening all known cirrhotics for HCC may lead to decreased mortality.
- 17 March 2011
- Published by BMJ in Frontline Gastroenterology
- Vol. 2 (3) , 182-187
Open AccessUtility of screening for hepatocellular carcinoma among cirrhotics
Background Screening known cirrhotics for hepatocellular cancer (HCC) has long been a contentious topic. Studies to date have failed to conclusively prove or disprove the validity of α-fetoprotein (AFP) and hepatic ultrasound as screening mechanisms for HCC among cirrhotics, particularly in the American population. It is not clear whether these screening mechanisms provide any benefit in terms of reduced morbidity and mortality. Methods The study examined all patients with liver cirrhosis who developed HCC at the Michael E DeBakey VA Medical Center between 1999 and 2005. Those who were screened with AFP and/or imaging (either ultrasound, triphasic liver protocol CT or MRI) were compared with those patients who were not screened at all. The screened and unscreened patients were compared in terms of Barcelona Clinic Liver Cancer (BCLC) stage at the time of diagnosis. Results Statistical analysis revealed a significant difference between the screened and unscreened groups in terms of BCLC stage at diagnosis, with the unscreened group being diagnosed at later stages than the screened group. Of the 155 patients observed, 26 were appropriately screened, and 129 were not. The BCLC stages at diagnosis for the two groups were as follows: screened patients: 34.6%, 38.5%, 7.7% and 19.2% for BCLC stages A, B, C and D, respectively; unscreened patients: 12.4%, 24.8%, 27.1% and 35.7% for BCLC stages A, B, C and D, respectively. The different trend in the two groups was found to be statistically significant, with a p value of 0.004. Furthermore, among the screened group, no particular method of screening (AFP vs imaging vs combination) was shown to be superior to another. Conclusions Screening for HCC among cirrhotics using AFP and/or imaging every 6 months does correlate with HCC diagnosis at an earlier BCLC stage, thus portending better treatment options and improved prognosis. Therefore, screening all known cirrhotics for HCC may lead to decreased mortality.